气虚证模型大鼠鼻咽组织cDNA阵列B区基因表达谱特征及其对治疗的反应

目的 :观察气虚证模型大鼠鼻咽组织B区基因表达谱特征及其对治疗的反应。方法 :药物加疲劳法在Wistar大鼠制作气虚证模型 ,随机分为治疗组与对照组 ,以AtlasTMcDNA阵列法检测各组动物鼻咽组织B区基因表达谱 ,比较分析其表达谱差异。结果 :模型组动物表现I -kBα链、MAPK1、MAPK2、GNB2基因表达上调 ,MEK5、PLCδ、RGP(Rab相关GTP结合蛋白 )基因表达下调 ;治疗 1周后 ,表达上调的MAPK1、MAPK2二基因活性恢复正常 ,其余 5个基因表达活性仍维持治疗前活性状态。结论 :单纯气虚证动物出现调制子、效应子和细胞内转导子基因表达活性异常 ,细胞内信号传导通路发生障碍。经针对性治疗后 ,这些障碍可以逐渐恢复正常。

肺纤维化(气虚血瘀证)大鼠模型造模方法新探索

[目的]探索内窥镜引导下制作肺纤维化(气虚血瘀证)大鼠模型的新方法。[方法]1)SD大鼠60只,运用内窥镜摄录监视系统及自创的鼠麻醉喉镜,采用无水乙醚吸入法麻醉方式,对大鼠气管内推注药物博莱霉素造肺纤维化模型。2)造模后随机分正常对照组,模型组,芪术合剂组,泼尼松组观察。中药芪术合剂组疗效显著,从以方测证的角度验证肺纤维化(气虚血瘀证)大鼠模型的制作成功。[结果]1)此造模方法具有气管内推注药物靶点准确,成功率高,无外源创伤,保障实验数据的原始性、可靠性,节约时间,提高工作效率,减少标本耗损量,降低实验成本。2)益气活血散结法中药干预以方测证结果表明,该方法制作的模型具有气虚血瘀证的病机特点。[结论]该方法的创新值得在肺系疾病大鼠模型制造实验中推广运用。

呼吸道生物被膜菌致肺气虚证大鼠模型的研制

目的:研制大鼠肺气虚证模型,为研究因慢性呼吸道感染导致肺气虚证的诊治提供可靠的实验动物。方法:健康SD大鼠随机分为空白对照组、烟熏对照组,以及高、中、低菌量模型组。模型组采用呼吸道生物被膜菌(bacterial biofilm,BF)铜绿假单胞菌滴鼻法,辅以寒冷疲劳刺激引起大鼠呼吸道慢性感染,诱导肺气虚证的发生。观察各组证候表现、游泳时间、体重变化、血液流变学指标的改变,以及肺支气管组织器官病理改变。结果:高、中、低菌量模型组大鼠的一般体征均符合肺气虚证,症状较烟熏组稳定。游泳时间和体重增加低于空白对照组,尤以高菌量组为明显(P<0.05,P<0.01)。血流变指标提示血液流变性有障碍,肺及支气管炎症明显,炎症的程度和感染菌量有关。结论:将呼吸道生物被膜菌(铜绿假单胞菌)以滴鼻法并辅以寒冷疲劳刺激,可以诱导大鼠肺气虚证模型,相关的指标表明证候表现与中医学理论的病机相符,且该模型具有稳固、易复制、贴近原型的特点。

Variations of energy metabolism and adenosine Triphosphatase activity in gastric mucosa in chronic atrophic gastritis rats with Qi deficiency and blood stasis syndrome and effect of Zhiweifangbian capsule

OBJECTIVE: To study the effects of Zhiweifangbian (ZWFB) capsule on lactic dehydrogenase (LDH), succinic dehydrogenase (SDH) and ATPase activities in gastric mucosa of chronic atrophic gastritis (CAG) rats with Qi deficiency and blood stasis syndrome. METHODS: Totally 90 rats were randomly divided into 2 groups: normal group (n=10) and modelgroup (n=80). The CAG rat model of Qi deficiency and blood stasis type was induced by synthetic methods. After modeling for 12 weeks and the successful CAG model was determined, the CAG model rats were divided by random number table into model group (MG), ZWFB high-dose group (ZWFBH), ZWFB middle-dose group (ZWFBM), ZWFB low-dose group (ZWFBL) and Weimeisu group (WM), 9 rats in each group. The rats in the normal and model groups were intragastrically administrated with distilled water, 10 mL/kg every day; the ZWFB high-dose group with ZWFB, 0.6 g/ kg -1 · d -1 ; the ZWFB middle-dose group with ZWFB, 0.3 g/kg -1 · d -1 ; the ZWFB low-dose group with ZWFB, 0.15 g/kg -1 · d -1 , and the WM group with suspension of WM , 0.25 g/kg -1 · d -1 . The treatment was given for 90 consecutive days. Then general survival states were observed and the activities of LDH, SDH, Na + -K + -ATPase and Ca 2+ -Mg 2+ -ATPase in gastric mucosa tissue were detected. RESULTS: Compared with the normal group, activity of LDH in the gastric mucosa (P<0.05) and activities of SDH, Na + -K + -ATPase and Ca 2+ -Mg 2+ -ATPase significantly decreased in the normal group (P<0.05). Compared with the model group the activity of LDH decreased and activities of SDH, Na + -K + -ATPase and Ca 2+ -Mg 2+ -ATPase significantly increased in the high dose ZWFB group (P<0.05). CONCLUSION: ZWFB capsule can promote energy metabolism and ATPase activity in the gastric mucosa cell, so as to protect the function of the gastric mucosa cell.